Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/1b Trial of E7777 in Peripheral T-Cell Lymphoma
jRCT2080221516Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of denileukin diftitox in peripheral T-cell lymphoma (PTCL), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum tolerated dose (MTD) and Recommended dose (RD). Started Jul 2011; status: completed.
02
Drugs
denileukin diftitox
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on jRCT2080221516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221516.